Don't overlook these 4 noteworthy advances in endocrinology
ALTERNATIVES TO PZI VET
In April, IDEXX Pharmaceuticals announced the discontinuation of PZI Vet (a porcine-and bovine-source protamine zinc insulin). Consider these options for switching cats from PZI Vet to other insulin preparations:
As noted above, glargine is a good insulin option, particularly in cats in which diabetes has been newly diagnosed. The commercially available form of glargine, Lantus, is a human insulin analogue produced by recombinant DNA technology. The production organism is a nonpathogenic laboratory strain of Escherichia coli. Each milliliter contains 100 IU (3.6378 mg) insulin glargine.
At a pH of 4, Lantus is designed to be completely soluble at a neutral pH. After injection into the subcutaneous tissue in people, the solution is neutralized, and microprecipitates form and slowly release small amounts of insulin glargine, resulting in a relatively constant concentration over 24 hours.
A study presented at the ACVIM Forum in 2005 showed that eight of eight diabetic cats treated with glargine twice daily and fed a low-carbohydrate, high-protein diet were in diabetic remission within four months, and six of seven were still in remission at one year.1 My clinical experience has been similar, with more than 50% of cats newly diagnosed with diabetes experiencing remission within two to four months when receiving glargine and a low-carbohydrate, high-protein diet. The recommended starting dose is 0.5 U/kg twice a day if the initial fasting blood glucose concentration is > 360 mg/dl and 0.25 U/kg twice a day if the initial fasting blood glucose concentration is < 360 mg/dl.1
If you decide to use glargine in your diabetic feline patients, I suggest these tips:
Canine hyperadrenocorticism has been most commonly treated with the adrenolytic drug mitotane (o,p'-DDD). However, mitotane has several side effects and is associated with a high frequency of relapses.
Trilostane is a synthetic, orally active steroid analogue. It can act as a competitive inhibitor of the 3-beta-hydroxysteroid dehydrogenase enzyme system and, thus, inhibit the synthesis of several steroids, including cortisol and aldosterone. This blockade is reversible and likely dose-related.
In the United Kingdom, trilostane is licensed to treat canine hyperadrenocorticism. Dechra Pharmaceuticals is pursuing U.S. FDA approval of trilostane for this condition.
The efficacy and safety of trilostane in treating canine pituitary-dependent hyperadrenocorticism (PDH) were evaluated in a multicenter European study.2 Seventy-eight dogs with confirmed PDH were treated with trilostane for up to three years. Trilostane appeared to be well-tolerated by almost all the dogs. Two dogs developed signs and biochemical evidence of hypoadrenocorticism. One of these dogs recovered with therapy; the other dog died despite withdrawing trilostane and administering therapy. Two additional dogs died within one week of starting trilostane, but a direct link with the trilostane therapy could not be established in either case.
The study revealed that trilostane was nearly as effective as mitotane in resolving signs of hyperadrenocorticism such as polyuria, polydipsia, polyphagia, and skin abnormalities.2 These improvements were maintained as long as the dogs received adequate doses of trilostane. Only eight dogs that were treated with trilostane for more than two months showed poor control of clinical signs. Mitotane is effective in controlling clinical signs in about 80% of cases of PDH but has a higher percentage of side effects than trilostane does.3
Trilostane also caused a significant reduction in the mean basal and post-ACTH stimulation cortisol concentrations.2 These improvements were also maintained for the duration of the trial. Thirty-five dogs had at least one dose adjustment during the treatment period.
The mean survival time of all trilostane-treated dogs was 661 days.2 Direct comparison with mitotane is difficult as 65% of the dogs were still alive at censoring, so the mean survival time may be higher. In comparison, the mean survival time of mitotane-treated dogs is 810 to 900 days.4,5 A recent study comparing trilostane (administered twice daily) to mitotane (administered by using the nonselective adrenocorticolysis protocol) demonstrated a significantly longer median survival time in the dogs treated with trilostane (900 days) than in the dogs treated with mitotane (720 days).5
Canine adrenal-dependent hyperadrenocorticism
Only a few cases of adrenal-dependent hyperadrenocorticism have been treated with trilostane. A reduction in post-ACTH cortisol concentrations has been demonstrated, and survival times of more than two years have been achieved in some cases.6,7 Because of an insufficient number of documented cases, it is impossible to compare the long-term efficacy of trilostane with that of mitotane in treating adrenal-dependent hyperadrenocorticism. Trilostane is not cytotoxic, and it is likely to be inferior to mitotane in preventing and controlling metastatic disease. The value of trilostane for preoperative therapy before adrenalectomy has not been systematically examined. However, given the data above, trilostane might be an effective and safer alternative to ketoconazole in this respect.